Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Rahim, Sung Kim, Hyeongryul So, Hyung Kim, G. Cheon, Eun Lee, K. Kang, D. Lee (2014)
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear OncologyNuclear Medicine and Molecular Imaging, 48
K. Pinker, C. Riedl, W. Weber (2017)
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developmentsEuropean Journal of Nuclear Medicine and Molecular Imaging, 44
N. Arslan, T. Miller, F. Dehdashti, R. Battafarano, B. Siegel (2002)
Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer.Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, 4 4
R. Ricotta, A. Verrioli, S. Ghezzi, L. Porcu, A. Grothey, A. Falcone, E. Cutsem, G. Argilés, A. Adenis, M. Ychou, C. Barone, O. Bouché, M. Peeters, Y. Humblet, L. Mineur, A. Sobrero, J. Hubbard, C. Cremolini, H. Prenen, J. Tabernero, H. Jarraya, T. Mazard, S. Deguelte-Lardière, K. Papadimitriou, M. Eynde, A. Pastorino, D. Redaelli, K. Bencardino, C. Funaioli, A. Amatu, G. Carlo-Stella, V. Torri, A. Sartore-Bianchi, A. Vanzulli, S. Siena (2016)
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)ESMO Open, 1
H. Uetake, K. Sugihara, K. Muro, T. Sunaya, Yuka Horiuchi‐Yamamoto, H. Takikawa (2017)
Clinical Features of Regorafenib‐induced Liver Injury in Japanese Patients From Postmarketing ExperienceClinical Colorectal Cancer, 17
R. Wahl, H. Jacene, Y. Kasamon, M. Lodge (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 50
H. Young, R. Baum, U. Cremerius, K. Herholz, O. Hoekstra, A. Lammertsma, J. Pruim, P. Price (1999)
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.European journal of cancer, 35 13
Jin Li, S. Qin, R. Xu, T. Yau, B. Ma, H. Pan, Jianming Xu, Y. Bai, Y. Chi, Li-wei Wang, K. Yeh, F. Bi, Ying Cheng, A. Le, Jen‐Kou Lin, Tianshu Liu, D. Ma, C. Kappeler, J. Kalmus, Tae Kim (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology, 16 6
K. Mross, A. Frost, S. Steinbild, S. Hedbom, M. Büchert, U. Fasol, C. Unger, J. Krätzschmar, R. Heinig, O. Boix, O. Christensen (2012)
A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsClinical Cancer Research, 18
M. Ogata, M. Kotaka, T. Ogata, Y. Hatachi, H. Yasui, Takeshi Kato, A. Tsuji, H. Satake (2020)
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in JapanPLoS ONE, 15
S. Larson, Y. Erdi, T. Akhurst, M. Mazumdar, H. Macapinlac, R. Finn, Cecille Casilla, M. Fazzari, N. Srivastava, H. Yeung, J. Humm, J. Guillem, R. Downey, M. Karpeh, Alfred Cohen, R. Ginsberg (1999)
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.Clinical positron imaging : official journal of the Institute for Clinical P.E.T, 2 3
F. Cornelis, E. Petre, E. Vakiani, D. Klimstra, J. Durack, M. Gonen, J. Osborne, S. Solomon, C. Sofocleous (2018)
Immediate Postablation 18F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver MetastasesThe Journal of Nuclear Medicine, 59
Cancer Program (2003)
Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
T. Bekaii-Saab, F. Ou, D. Ahn, P. Boland, K. Ciombor, Erica Heying, T. Dockter, N. Jacobs, B. Pasche, J. Cleary, J. Meyers, R. Desnoyers, Jeannine McCune, Jeannine McCune, K. Pedersen, A. Barzi, E. Chiorean, E. Chiorean, Jeff Sloan, M. Lacouture, H. Lenz, A. Grothey (2019)
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.The Lancet. Oncology
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
A. Avallone, L. Aloj, B. Pecori, C. Caracó, A. Stefano, F. Tatangelo, L. Silvestro, V. Granata, F. Bianco, C. Romano, F. Gennaro, A. Budillon, A. Petrillo, P. Muto, G. Botti, P. Delrio, S. Lastoria (2019)
18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal CancerThe Journal of Nuclear Medicine, 60
D. Strumberg, M. Scheulen, B. Schultheis, H. Richly, A. Frost, M. Büchert, O. Christensen, M. Jeffers, R. Heinig, O. Boix, K. Mross (2012)
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyBritish Journal of Cancer, 106
A. Grothey, E. Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H. Lenz, R. Goldberg, D. Sargent, F. Cihon, L. Cupit, A. Wagner, D. Laurent (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 381
S. Moon, S. Hyun, J. Choi (2012)
Prognostic Significance of Volume-Based PET Parameters in Cancer PatientsKorean Journal of Radiology, 14
(Common Terminology Criteria for Adverse Events v4.0 (CTCAE). (2009) (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf).)
Common Terminology Criteria for Adverse Events v4.0 (CTCAE). (2009) (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf).Common Terminology Criteria for Adverse Events v4.0 (CTCAE). (2009) (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf)., Common Terminology Criteria for Adverse Events v4.0 (CTCAE). (2009) (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf).
F. Cornelis, Vlasios Storchios, E. Violari, C. Sofocleous, H. Schoder, J. Durack, R. Siegelbaum, M. Maybody, J. Humm, S. Solomon (2016)
18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis AblationThe Journal of Nuclear Medicine, 57
IntroductionRegorafenib is a multikinase inhibitor approved for the treatment of metastatic colorectal cancer (mCRC). Despite providing a statistically significant survival benefit, a substantial number of patients fail to respond to or continue with treatment, which has resulted in an unmet clinical need for a biomarker of regorafenib efficacy.MethodsThe JACCRO CC-12 study was a prospective, multicenter, single-arm phase II trial designed to evaluate the usefulness of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) as an imaging biomarker of regorafenib in patients with mCRC that progressed after standard chemotherapies. FDG-PET and contrast-enhanced computed tomography (CT) were performed before and after treatment with regorafenib 160 mg once daily 3 weeks on/1 week off. The primary end point was the change in the maximum standardized uptake value in the lesion with the highest uptake at pre-treatment FDG-PET. The secondary end points included overall survival (OS), progression-free survival (PFS), the objective response rate (ORR), safety, and the correlation between FDG-PET and CT.ResultsTwenty patients were enrolled from November 2014 to March 2016, 17 of whom were evaluated for metabolic and morphological changes. Metabolic response with FDG-PET was partial response (PR) in one case (5.9%), stable disease (SD) in four (23.5%), and progressive disease (PD) in 12 (70.6%). The metabolic response rate was 5.9%. On CT imaging, no complete response or PR was observed, and the ORR was 0%. Median PFS and OS were 1.7 and 9.8 months, respectively. The median PFS of patients who achieved PR or SD by FDG-PET was 3.7 months, whereas that of those assessed as PD was 1 month (p = 0.13). The median OS of patients who achieved PR or SD by FDG-PET was 13.0 months, whereas that of patients assessed as PD was 10.6 months (p = 0.43). Frequent adverse events were palmar–plantar erythrodysesthesia syndrome, hypertension, loss of appetite, and fatigue.ConclusionsIn this study, FDG-PET failed to demonstrate usefulness as an early imaging biomarker of regorafenib in patients with mCRC.
Oncology and Therapy – Springer Journals
Published: Dec 1, 2021
Keywords: Colorectal cancer; Regorafenib; FDG-PET; Metabolic response; Biomarker
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.